{"id":"acalabrutinib-acp-196","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Diarrhea"},{"rate":"15-25","effect":"Headache"},{"rate":"20-30","effect":"Fatigue"},{"rate":"20-30","effect":"Infections"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-15","effect":"Anemia"},{"rate":"10-15","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3707348","moleculeType":"Small molecule","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acalabrutinib covalently binds to BTK, a key enzyme in B-cell receptor signaling, preventing activation of downstream pathways critical for malignant B-cell survival and proliferation. By selectively targeting BTK with minimal off-target effects, it reduces tumor burden in B-cell malignancies while potentially sparing normal immune function compared to less selective BTK inhibitors.","oneSentence":"Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:41.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Mantle cell lymphoma (MCL)"}]},"trialDetails":[{"nctId":"NCT02477696","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-07-28","conditions":"Chronic Lymphocytic Leukemia","enrollment":533},{"nctId":"NCT05388006","phase":"PHASE2","title":"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-01-05","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT02717611","phase":"PHASE2","title":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-03-08","conditions":"Chronic Lymphocytic Leukemia","enrollment":60},{"nctId":"NCT02586857","phase":"PHASE1, PHASE2","title":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-01-25","conditions":"Glioblastoma Multiforme","enrollment":24},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT02180724","phase":"PHASE2","title":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-09-11","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":107},{"nctId":"NCT05256641","phase":"PHASE1, PHASE2","title":"Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2023-01-23","conditions":"Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma","enrollment":24},{"nctId":"NCT04169737","phase":"PHASE2","title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":168},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT05336812","phase":"PHASE2","title":"Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-09-13","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":52},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT03946878","phase":"PHASE2","title":"Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-13","conditions":"Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive","enrollment":32},{"nctId":"NCT02213926","phase":"PHASE2","title":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-03-02","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":124},{"nctId":"NCT04883437","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-09-03","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":49},{"nctId":"NCT03516617","phase":"PHASE2","title":"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-09-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":120},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT02029443","phase":"PHASE1, PHASE2","title":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-01-30","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":306},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT03328273","phase":"PHASE1","title":"A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2018-01-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT02337829","phase":"PHASE2","title":"Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":48},{"nctId":"NCT06054776","phase":"PHASE2","title":"Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-02","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT04505254","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT02296918","phase":"PHASE1","title":"Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia","enrollment":69},{"nctId":"NCT06757647","phase":"PHASE2","title":"Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Seema Bhat","startDate":"2025-05-27","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":61},{"nctId":"NCT02362035","phase":"PHASE1, PHASE2","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-02-20","conditions":"Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL)","enrollment":161},{"nctId":"NCT02328014","phase":"PHASE1, PHASE2","title":"Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-20","conditions":"Non-Hodgkins Lymphoma, Multiple Myeloma, B-All","enrollment":40},{"nctId":"NCT04008706","phase":"PHASE3","title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":552},{"nctId":"NCT04484012","phase":"PHASE2","title":"Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-12-31","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":36},{"nctId":"NCT04189757","phase":"PHASE2","title":"Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-07","conditions":"Mantle Cell Lymphoma","enrollment":9},{"nctId":"NCT04941716","phase":"PHASE2","title":"Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-05-31","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT04765111","phase":"PHASE2","title":"Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-30","conditions":"Mantle Cell Lymphoma","enrollment":53},{"nctId":"NCT05943496","phase":"PHASE1","title":"Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-10-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT04198922","phase":"PHASE2","title":"Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-11","conditions":"Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":51},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT02180711","phase":"PHASE1, PHASE2","title":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-12-29","conditions":"Non Hodgkin Lymphoma","enrollment":113},{"nctId":"NCT04257578","phase":"PHASE1, PHASE2","title":"Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2020-12-02","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma","enrollment":23},{"nctId":"NCT02475681","phase":"PHASE3","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":535},{"nctId":"NCT02157324","phase":"PHASE1","title":"Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-08-18","conditions":"Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT04883749","phase":"PHASE2","title":"Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2021-06-01","conditions":"Chronic Lymphoid Leukemia","enrollment":53},{"nctId":"NCT03863184","phase":"PHASE2","title":"Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-10-11","conditions":"Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT04548648","phase":"PHASE2","title":"A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-10-15","conditions":"Central Nervous System Lymphoma","enrollment":10},{"nctId":"NCT04189952","phase":"PHASE2","title":"Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2020-09-22","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT04657094","phase":"PHASE2","title":"Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-16","conditions":"Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":4},{"nctId":"NCT04630756","phase":"PHASE1, PHASE2","title":"AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-17","conditions":"Advanced Haematological Malignancies","enrollment":40},{"nctId":"NCT04404088","phase":"PHASE2","title":"Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-16","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":60},{"nctId":"NCT03787264","phase":"PHASE2","title":"Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2019-01-14","conditions":"Chronic Lymphoid Leukemia","enrollment":46},{"nctId":"NCT03836261","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2019-02-25","conditions":"Chronic Lymphocytic Leukemia","enrollment":984},{"nctId":"NCT02112526","phase":"PHASE1","title":"Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-08-07","conditions":"Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)","enrollment":21},{"nctId":"NCT04783415","phase":"PHASE2","title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-26","conditions":"Mantle Cell Lymphoma","enrollment":12},{"nctId":"NCT04337827","phase":"PHASE2","title":"Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder","status":"TERMINATED","sponsor":"Deepa Jagadeesh","startDate":"2020-09-02","conditions":"Post-transplant Lymphoproliferative Disorder","enrollment":6},{"nctId":"NCT04626791","phase":"PHASE2","title":"Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-08-03","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT05214183","phase":"PHASE2","title":"Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nordic Lymphoma Group","startDate":"2021-12-15","conditions":"MCL, Mantle Cell Lymphoma","enrollment":81},{"nctId":"NCT03527147","phase":"PHASE1","title":"Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2018-06-19","conditions":"NHL, DLBCL, Non-hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT04502394","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","status":"UNKNOWN","sponsor":"Kartos Therapeutics, Inc.","startDate":"2021-02-23","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma","enrollment":84},{"nctId":"NCT04836832","phase":"PHASE1","title":"Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"Narendranath Epperla","startDate":"2022-07-01","conditions":"Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma","enrollment":""},{"nctId":"NCT04660045","phase":"PHASE2","title":"Early Intervention With Acalabrutinib in Patients With High Risk CLL","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2022-05","conditions":"Chronic Lymphocytic Leukemia, CLL/SLL","enrollment":""},{"nctId":"NCT05140096","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2020-01-03","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT04914936","phase":"PHASE1","title":"A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-09-21","conditions":"Healthy Participants","enrollment":72},{"nctId":"NCT04905043","phase":"PHASE1","title":"A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-06-03","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT04901923","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-03-15","conditions":"Healthy Participants","enrollment":59},{"nctId":"NCT04898101","phase":"PHASE1","title":"A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-03-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT04876807","phase":"PHASE1","title":"A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-01-28","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT04867941","phase":"PHASE1","title":"A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-10-21","conditions":"Hepatic Insufficiency","enrollment":18},{"nctId":"NCT04867980","phase":"PHASE1","title":"A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-04-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT03205046","phase":"PHASE1, PHASE2","title":"A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies","status":"TERMINATED","sponsor":"Acerta Pharma BV","startDate":"2017-06-29","conditions":"DLBCL, Richter Syndrome","enrollment":25},{"nctId":"NCT02211014","phase":"PHASE1","title":"An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-02","conditions":"Multiple Myeloma (MM)","enrollment":27},{"nctId":"NCT02362048","phase":"PHASE2","title":"ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-05","conditions":"Metastatic Pancreatic Cancer","enrollment":77},{"nctId":"NCT02537444","phase":"PHASE2","title":"Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-11","conditions":"Ovarian Cancer","enrollment":78},{"nctId":"NCT02454179","phase":"PHASE2","title":"Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-05","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":78},{"nctId":"NCT02448303","phase":"PHASE2","title":"Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":74},{"nctId":"NCT02351739","phase":"PHASE2","title":"Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-04","conditions":"Metastatic Urothelial Carcinoma","enrollment":78},{"nctId":"NCT02570711","phase":"PHASE2","title":"Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Acerta Pharma BV","startDate":"2015-10-13","conditions":"Metastatic Pancreatic Cancer","enrollment":3},{"nctId":"NCT02387762","phase":"PHASE2","title":"ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-04","conditions":"Rheumatoid Arthritis","enrollment":31},{"nctId":"NCT02735876","phase":"PHASE3","title":"A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Acerta Pharma BV","startDate":"2016-05","conditions":"Mantle Cell Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Acalabrutinib"],"phase":"phase_3","status":"active","brandName":"Acalabrutinib (ACP-196)","genericName":"Acalabrutinib (ACP-196)","companyName":"Acerta Pharma BV","companyId":"acerta-pharma-bv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}